Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abeba Habtesion

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Digestive Diseases and Sciences|May 3, 2021
Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor DevelopmentFatma El Zahraa Mohamed, Rajiv Jalan, Shane Minogue, et al.
Journal of Hepatology|September 12, 2018
Impaired brain glymphatic flow in experimental hepatic encephalopathyAnna Hadjihambi, Ian F Harrison, Marta Costas-Rodríguez, et al.
Journal of Hepatology|January 9, 2019
Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49]Anna Hadjihambi, Ian F Harrison, Marta Costas-Rodríguez, et al.
Frontiers in Cell and Developmental Biology|August 2, 2021
The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ InjuryUgo Soffientini, Nigel Beaton, Sukriti Baweja, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2026
Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver diseaseKaren Louise Thomsen, Vikram Sharma, Helen Jones, et al.
Journal of Hepatology|January 29, 2020
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failureCornelius Engelmann, Mohammed Sheikh, Shreya Sharma, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 4, 2014
Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinomaFatma E Mohamed, Rajai M Al-Jehani, Shane S Minogue, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver DiseaseFrancesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, et al.
Science Advances|March 7, 2025
Hyperammonemia induces programmed liver cell deathAnnarein J C Kerbert, Cornelius Engelmann, Abeba Habtesion, et al.
Gut|April 15, 2024
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosisJinxia Liu, Jane MacNaughtan, Annarein J C Kerbert, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Digestive Diseases and Sciences|May 3, 2021
Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor DevelopmentFatma El Zahraa Mohamed, Rajiv Jalan, Shane Minogue, et al.
Journal of Hepatology|September 12, 2018
Impaired brain glymphatic flow in experimental hepatic encephalopathyAnna Hadjihambi, Ian F Harrison, Marta Costas-Rodríguez, et al.
Journal of Hepatology|January 9, 2019
Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49]Anna Hadjihambi, Ian F Harrison, Marta Costas-Rodríguez, et al.
Frontiers in Cell and Developmental Biology|August 2, 2021
The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ InjuryUgo Soffientini, Nigel Beaton, Sukriti Baweja, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2026
Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver diseaseKaren Louise Thomsen, Vikram Sharma, Helen Jones, et al.
Journal of Hepatology|January 29, 2020
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failureCornelius Engelmann, Mohammed Sheikh, Shreya Sharma, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 4, 2014
Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinomaFatma E Mohamed, Rajai M Al-Jehani, Shane S Minogue, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver DiseaseFrancesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, et al.
Science Advances|March 7, 2025
Hyperammonemia induces programmed liver cell deathAnnarein J C Kerbert, Cornelius Engelmann, Abeba Habtesion, et al.
Gut|April 15, 2024
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosisJinxia Liu, Jane MacNaughtan, Annarein J C Kerbert, et al.
Pageof 2